Imperial College Receives £4.46 Million for Dementia Research Projects

The Michael Uren Foundation's significant donation will fund three new projects focused on understanding and treating dementia.

Generic image of abstract scientific research and funding elements.
AI

Generic image of abstract scientific research and funding elements.

Imperial College London has received a £4.46 million donation from the Michael Uren Foundation to fund three new research projects aimed at understanding dementia and accelerating the development of new treatments.

The substantial gift will support groundbreaking work building on recent discoveries in Imperial's Department of Brain Sciences and the UK Dementia Research Institute (UK DRI) at Imperial. These projects will explore links between dementia and other conditions, and address barriers to developing effective treatments.
This funding follows a previous £7.5 million gift from the Foundation in 2022, which supported four Alzheimer's disease research projects at Imperial. Professor Paul Matthews, Edmond and Lily Safra Chair in the Department of Brain Sciences, expressed gratitude for the Foundation's continued support, highlighting how it enables high-risk explorations and exciting discoveries.
The three newly funded projects include: 'Developing patent-protected drugs targeting TSPO', led by Professor David Owen, which focuses on protecting the brain's blood vessels by targeting the TSPO protein; 'Gene prioritisation for small vessel disease and dementia', led by Dr Alexi Nott and Professor Paul Matthews, investigating genes active in brain blood vessel cells; and 'Tackling dual pathologies in Alzheimer’s and Parkinson’s', led by Dr Naoto Watamura and Dr Sam Barnes, studying the interaction of tau and -synuclein proteins in the brain.
“

"By linking these stages together, we can accelerate the journey from scientific insight to treatments that have the potential to benefit patients."

Professor David Owen · Clinical Professor of Pharmacology, Department of Brain Sciences at Imperial College London
These projects aim to translate early scientific insights into realistic pathways for new treatments, with the potential to benefit millions worldwide affected by dementia. The research is expected to provide a genetics-backed map of therapeutic targets, particularly in the brain's blood vessels, which could accelerate future drug development.
Based on information from the official source: Imperial College London (17/11/2026)